Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer
Fas/CD95 在三阴性乳腺癌中的新型免疫抑制活性
基本信息
- 批准号:10661817
- 负责人:
- 金额:$ 45.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-07 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:Antitumor ResponseBindingBinding ProteinsBiochemicalBiological AssayBreast Cancer CellC-terminalCD95 AntigensCancer EtiologyCellsCessation of lifeClinicClinicalComplementComplexDataEquilibriumFas Signaling PathwayGenetic RecombinationGenetic TranscriptionGenetically Engineered MouseGoalsGrowthImmuneImmune checkpoint inhibitorImmunocompetentImmunosuppressionImmunotherapyImplantIn VitroInduction of ApoptosisInfiltrationInflammatoryKiller CellsKnock-outKnockout MiceKnowledgeLigandsLymphocytic InfiltrateMalignant NeoplasmsMediatingModelingMolecularMouse Cell LineMouse StrainsMusMyeloid-derived suppressor cellsNF-Kappa B p65NF-kappa BNMR SpectroscopyNatural Killer CellsNatureNeoplasm MetastasisOutcomePatientsProductionPrognosisPrognostic FactorPublic HealthRoleSignal TransductionTNFRSF5 geneTNFRSF6 geneTestingTissuesTumor PromotionWomanWorkcancer cellcancer subtypescancer therapycrosslinkcytokinederepressiondesignimmune activationimmune checkpointimprovedin vivoinhibitormalignant breast neoplasmmolecular subtypesmouse modelneoplastic cellnovelp65peptidomimeticspermissivenessprogramsprotein complexreceptorrecruitscreeningsingle-cell RNA sequencingsmall molecule librariestargeted treatmenttriple-negative invasive breast carcinomatumortumor growthtumor microenvironmentubiquitin ligase
项目摘要
Summary
Among women, breast cancer (BC) is the most common malignancy, and the second leading cause of cancer
death. Patients with basal/triple negative BC (TNBC) have the poorest clinical outcome with no targeted
therapies available when compared to other molecular subtypes. Fas/CD95 is a well characterized death
receptor that in permissive cells mediates induction of apoptosis when stimulated by its cognate ligand, FasL. It
is now well established that Fas also has multiple nonapoptotic, tumor promoting functions. High Fas
expression is a negative prognostic factor for TNBC. We have previously demonstrated in multiple genetically
engineered mouse tumor models with tissue specific deletion of Fas that cancer cells maintain Fas expression
and without Fas tumors do not grow. However, some tumors still formed in these knock-out (KO) mice due to
‘escapers’ from Cre recombination. It remained unclear whether this activity of Fas was cell autonomous or
required cells of the tumor microenvironment. New preliminary data on a mouse model of TNBC now suggest
that tumor cell expressed Fas exerts an immune suppressive activity promoting recruitment of myeloid derived
suppressor cells (MDSCs) resulting in inhibition of tumor infiltration by natural killer (NK) cells. Most recently
we discovered, KPC2, a novel Fas interaction partner that binds to the C-terminal end and in unstimulated
TNBC cells sequesters both the NF-κB subunit p65 and KPC1, a ubiquitin ligase that degrades the p50
precursor p105. We found that when Fas is eliminated p105 gets degraded shifting the balance of NF-κB
subunits from repressive p50/p50 homodimers to transcriptionally active p50/p65 heterodimers. That in turn
unleashes production of a number of proinflammatory cytokines that regulate the recruitment of a number of
immune cells including NK cells. Based on these preliminary data we hypothesize that in TNBC Fas acts as a
novel immune check point for NK cells likely by remodeling the immune landscape, that a novel Fas bound
protein complex around KPC2 is responsible for this immune suppressive activity of Fas and finally, that
disrupting this interaction unleashes an antitumor activity that can be used to target TNBC cells. These
hypotheses will be studied in two specific aims: Specific Aim 1: Characterize immune suppressive activities of
Fas in triple negative breast cancer. Specific Aim 2: To determine how Fas expression suppresses a
proinflammatory program. The goal of this project is to characterize novel activities of Fas in promoting TNBC
growth and metastasis as well as its immune suppressive function on NK cells. The project will increase our
knowledge on the role of a complex and critical receptor/ligand signaling pair in cancer that has long been
misunderstood. Only recently has inhibition of FasL (and not its use) been recognized as a valuable option for
the treatment of cancer in the clinic. In TNBC our work now points at inhibiting the Fas receptor in addition to
its ligand. Finally, the novel immune suppressive activity of Fas provides a compelling rationale to combine
Fas/FasL inhibition with conventional checkpoint inhibitors for the treatment of TNBC.
总结
在女性中,乳腺癌(BC)是最常见的恶性肿瘤,也是第二大癌症原因
死亡基础/三阴性BC(TNBC)患者的临床结局最差,
与其他分子亚型相比,Fas/CD 95是一种良好表征的死亡
受体,当受其同源配体FasL刺激时,在允许细胞中介导凋亡的诱导。它
Fas也具有多种非凋亡的促肿瘤功能。高Fas
表达是TNBC的负预后因素。我们之前已经在多个基因组中证明了
具有组织特异性Fas缺失的工程化小鼠肿瘤模型,癌细胞保持Fas表达
没有Fas,肿瘤就不会生长。然而,一些肿瘤仍然在这些敲除(KO)小鼠中形成,这是由于
从Cre重组中逃脱。目前还不清楚Fas的这种活性是细胞自主的,还是
肿瘤微环境所需的细胞。关于TNBC小鼠模型的新的初步数据现在表明
肿瘤细胞表达Fas发挥免疫抑制活性,促进髓源性
抑制细胞(MDSC),导致自然杀伤(NK)细胞抑制肿瘤浸润。最近
我们发现,KPC 2,一种新的Fas相互作用伴侣,结合到C末端,在未受刺激的情况下,
TNBC细胞隔离NF-κB亚基p65和KPC 1,KPC 1是一种降解p50的泛素连接酶
前体P105。我们发现,当Fas被清除时,p105被降解,改变了NF-κB的平衡,
从抑制性p50/p50同源二聚体到转录活性p50/p65异源二聚体。这反过来
释放大量促炎细胞因子的产生,这些细胞因子调节大量
免疫细胞包括NK细胞。基于这些初步数据,我们假设在TNBC中Fas作为一种免疫调节剂,
NK细胞的新免疫检查点可能通过重塑免疫景观,即新的Fas结合
KPC 2周围的蛋白复合物负责Fas的免疫抑制活性,
破坏这种相互作用释放出可用于靶向TNBC细胞的抗肿瘤活性。这些
将在两个具体目标中研究假设:具体目标1:表征
Fas在三阴性乳腺癌中的应用。具体目标2:确定Fas表达如何抑制细胞凋亡,
促炎程序本项目的目标是表征Fas在促进TNBC中的新活性
生长和转移以及对NK细胞的免疫抑制作用。该项目将增加我们的
关于复杂和关键的受体/配体信号传导对在癌症中的作用的知识,
误会了直到最近,FasL的抑制(而不是其使用)才被认为是治疗癌症的有价值的选择。
在临床上治疗癌症在TNBC中,我们的工作现在指向抑制Fas受体,除了
其配体。最后,Fas新的免疫抑制活性为联合收割机
用常规检查点抑制剂抑制Fas/FasL用于治疗TNBC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marcus E. Peter其他文献
Expression of c-FLIP<sub>L</sub> and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide
- DOI:
10.1182/blood.v95.11.3478 - 发表时间:
2000-06-01 - 期刊:
- 影响因子:
- 作者:
Fabienne Willems;Zoulikha Amraoui;Nathalie Vanderheyde;Valérie Verhasselt;Ezra Aksoy;Carsten Scaffidi;Marcus E. Peter;Peter H. Krammer;Michel Goldman - 通讯作者:
Michel Goldman
Mapping of Ras-related GTP-binding proteins by GTP overlay following two-dimensional gel electrophoresis.
二维凝胶电泳后通过 GTP 覆盖图绘制 Ras 相关 GTP 结合蛋白。
- DOI:
- 发表时间:
1994 - 期刊:
- 影响因子:11.1
- 作者:
Lukas A. Huber;Oliver Ullrich;Y. Takai;Anne Lütcke;Paul Dupree;V. Olkkonen;H. Virta;M. J. D. Hoop;Kirill Alexandrov;Marcus E. Peter;Marino Zerial;Kai Simons - 通讯作者:
Kai Simons
AIDS and the death receptors.
艾滋病和死亡受体。
- DOI:
- 发表时间:
1997 - 期刊:
- 影响因子:6.7
- 作者:
Marcus E. Peter;A. Ehret;Christina Berndt;P. H. Krammer - 通讯作者:
P. H. Krammer
The two CD95 apoptosis signaling pathways may be a way of cells to respond to different amounts and/or forms of CD95 ligand produced in different tissues
这两条CD95凋亡信号通路可能是细胞对不同组织中产生的不同量和/或形式的CD95配体作出反应的一种方式
- DOI:
10.1038/sj.cdd.4400707 - 发表时间:
2000 - 期刊:
- 影响因子:12.4
- 作者:
Ingo Schmitz;Henning Walczak;P. H. Krammer;Marcus E. Peter - 通讯作者:
Marcus E. Peter
APO‐1(CD95)‐mediated apoptosis in Jurkat cells does not involve src kinases or CD45
Jurkat 细胞中 APO-1(CD95) 介导的细胞凋亡不涉及 src 激酶或 CD45
- DOI:
- 发表时间:
1995 - 期刊:
- 影响因子:3.5
- 作者:
B. Schraven;Marcus E. Peter - 通讯作者:
Marcus E. Peter
Marcus E. Peter的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marcus E. Peter', 18)}}的其他基金
Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer
Fas/CD95 在三阴性乳腺癌中的新型免疫抑制活性
- 批准号:
10514907 - 财政年份:2022
- 资助金额:
$ 45.11万 - 项目类别:
DISE - a natural cancer surveillance mechanism - a new road to cancer therapy
DISE——天然癌症监测机制——癌症治疗新之路
- 批准号:
9313238 - 财政年份:2015
- 资助金额:
$ 45.11万 - 项目类别:
DISE - a natural cancer surveillance mechanism - a new road to cancer therapy
DISE——天然癌症监测机制——癌症治疗新之路
- 批准号:
9753713 - 财政年份:2015
- 资助金额:
$ 45.11万 - 项目类别:
DISE - a natural cancer surveillance mechanism - a new road to cancer therapy
DISE——天然癌症监测机制——癌症治疗新之路
- 批准号:
10224839 - 财政年份:2015
- 资助金额:
$ 45.11万 - 项目类别:
DICE - a natural cancer surveillance mechanism - a new road to cancer therapy
DICE——自然癌症监测机制——癌症治疗新之路
- 批准号:
9122387 - 财政年份:2015
- 资助金额:
$ 45.11万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
- 批准号:
DP240103141 - 财政年份:2024
- 资助金额:
$ 45.11万 - 项目类别:
Discovery Projects
Structural classification of NHEJ pathways; unravelling the role of Ku-binding proteins
NHEJ通路的结构分类;
- 批准号:
MR/X00029X/1 - 财政年份:2023
- 资助金额:
$ 45.11万 - 项目类别:
Research Grant
BRC-BIO: Evolutionary Patterns of Ice-Binding Proteins in North Pacific Intertidal Invertebrates
BRC-BIO:北太平洋潮间带无脊椎动物冰结合蛋白的进化模式
- 批准号:
2312378 - 财政年份:2023
- 资助金额:
$ 45.11万 - 项目类别:
Standard Grant
Exploring the roles and functions of sex steroid hormone receptor-associated RNA binding proteins in the development of geriatric diseases.
探索性类固醇激素受体相关 RNA 结合蛋白在老年疾病发展中的作用和功能。
- 批准号:
23K06408 - 财政年份:2023
- 资助金额:
$ 45.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
UV Plasmon-Enhanced Chiroptical Spectroscopy of Membrane-Binding Proteins
膜结合蛋白的紫外等离子增强手性光谱
- 批准号:
10680969 - 财政年份:2023
- 资助金额:
$ 45.11万 - 项目类别:
Investigating physiologic and pathophysiologic connections between the Parkinson's disease protein alpha-synuclein and RNA binding proteins
研究帕金森病蛋白 α-突触核蛋白和 RNA 结合蛋白之间的生理和病理生理联系
- 批准号:
10744556 - 财政年份:2023
- 资助金额:
$ 45.11万 - 项目类别:
Structural and computational analysis of immune-related RNA-binding proteins
免疫相关 RNA 结合蛋白的结构和计算分析
- 批准号:
23K06597 - 财政年份:2023
- 资助金额:
$ 45.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Characterization of carbohydrate-binding proteins and their applications
碳水化合物结合蛋白的表征及其应用
- 批准号:
23K05034 - 财政年份:2023
- 资助金额:
$ 45.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A machine learning approach to identify carbon dioxide-binding proteins for sustainability and health
一种机器学习方法来识别二氧化碳结合蛋白以实现可持续发展和健康
- 批准号:
2838427 - 财政年份:2023
- 资助金额:
$ 45.11万 - 项目类别:
Studentship
The role of RNA binding proteins in heart development and congenital heart defects
RNA结合蛋白在心脏发育和先天性心脏缺陷中的作用
- 批准号:
10827567 - 财政年份:2023
- 资助金额:
$ 45.11万 - 项目类别: